An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped. Their finding was published in the New England Journal of Medicine in an article co-authored by 14 researchers, including Dr. Jean-Pierre Routy of the Research Institute of the McGill University Health Centre (RI-MUHC).
IL-2 is currently used as a complement to highly active antiretroviral therapy (known as HAART), which is administered to patients with HIV-AIDS. Since HAART controls replication of viruses in the blood, doctors thought that IL-2 would help regenerate more CD4+ immune cells, which serve as an indicator of viral progression. It was thought that IL-2 increased the natural immunity of patients by helping immune cells mature and multiply.
“Our results show that IL-2 has no effect on the development of AIDS or on patient survival,” says Dr. Routy. “More precisely, while the presence of IL-2 leads to a faster increase of CD4+ immune cells, these cells are less functional than the CD4+ cells that regenerate naturally in patients who do not receive IL-2. This means that IL-2 treatment provides no benefit and does not prevent AIDS-related infectious diseases.”
“For the first time, a study has shed light on recurring questions concerning the value of biological markers and their limitations in assessing patient health,” explains Dr. Routy. “Our challenge now will be to develop tests that assess the function of immune cells and not simply their quantity. This will ensure that HIV treatments indeed have a clinical benefit for patients.”
This 8-year study involved over 5000 patients in 25 countries, and was one of the largest ever conducted on HIV-AIDS. “The fact that data from developing countries was used in biomedical research on innovative compounds is very revolutionary in the history of HIV-AIDS research,” explains Dr. Routy.
Dr. Jean-Pierre Routy is a physician in the Division of Hematology and Immunodeficiency at the MUHC as well as a researcher in the Infection and Immunity Axis at the Research Institute of the MUHC. He is also an Associate Professor of Hematology at McGill University and a senior clinical researcher with the Fonds de la recherche en santé du Québec (FRSQ).
The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, the university health center affiliated with the Faculty of Medicine at McGill University. The institute supports over 600 researchers, nearly 1200 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge.
The Research Institute of the MUHC is supported in part by the Fonds de la recherche en santé du Québec. For further details visit: www.muhc.ca/research
You will find this press release, with the original article and a short audio interview by following this link:http://www.muhc.ca/media/news/
For more information please contact:Julie Robert
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences